(Q38267662)

1 September 2017

1 reference

title

Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children (English)

1 reference

inflammatory bowel diseases

1 September 2017

0 references

probiotics

0 references

inflammation

0 references

irritable bowel syndrome

1 reference

S Guandalini

1

1 reference

PubMed ID

25391345

1 September 2017

E Cernat

series ordinal

2

1 reference

PubMed ID

25391345

1 September 2017

D Moscoso

series ordinal

3

1 reference

1 September 2017

1 January 2015

1 reference

1 September 2017

1 reference

1 September 2017

6

1 reference

1 September 2017

2

1 reference

1 September 2017

209-217

1 reference

Therapeutic potential of two probiotics in inflammatory bowel disease as observed in the trinitrobenzene sulfonic acid model of colitis

1 September 2017

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Saccharomyces boulardii does not prevent relapse of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Dietary fructo-oligosaccharides and lactulose inhibit intestinal colonisation but stimulate translocation of salmonella in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Management of the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Therapeutic effects of four strains of probiotics on experimental colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

The interplay between the intestinal microbiota and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Molecular analysis of the gut microbiota of identical twins with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Meta-analysis of probiotics for the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

A comparative study of the preventative effects exerted by three probiotics, Bifidobacterium lactis, Lactobacillus casei and Lactobacillus acidophilus, in the TNBS model of rat colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Childhood functional gastrointestinal disorders: child/adolescent.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Post-infectious functional gastrointestinal disorders in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Inflammatory bowel disease pathogenesis: what is new?

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Lactobacillus GG in inducing and maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Guidelines on the irritable bowel syndrome: mechanisms and practical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Mechanisms and efficacy of dietary FODMAP restriction in IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Effect of the consumption of a fermented dairy product containing Bifidobacterium lactis DN-173 010 on constipation in childhood: a multicentre randomised controlled trial (NTRTC: 1571).

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Use of complementary medicine in pediatric patients with inflammatory bowel disease: results from a multicenter survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Lactobacillus fermentum ACA-DC 179 displays probiotic potential in vitro and protects against trinitrobenzene sulfonic acid (TNBS)-induced colitis and Salmonella infection in murine models

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.3920%2FBM2014.0067

21 January 2018

Identifiers

DOI

10.3920/BM2014.0067

1 reference

1 September 2017

1 reference

PubMed ID

25391345